Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR to Initiate PI/II Study in March of Therapeutic Enzyme for Hunter Syndrome that Applies Blood-Brain Barrier Technology
January 20, 2017
- Ethical Drug Sales Down 3.6% in November: Crecon Report
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Nichi-Iko, Meiji Seika Pharma Obtain New Indications for Zosyn Generics
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
- Mitsubishi Tanabe to Shake Up Organization in April
January 17, 2017
- Eisai to Take Over Rights to Roche/Chugai’s Insomnia Drug
January 17, 2017
- FDA Orphan Status Granted to Nippon Shinyaku’s DMD Med
January 17, 2017
- Dasotraline Meets Primary Endpoint in PII/III Study in Adult Patients with Binge Eating Disorder: Sumitomo Dainippon
January 17, 2017
- Hisamitsu Suffers Double-Digit Plunge in March-November Sales
January 16, 2017
- Shionogi’s Novel Antibacterial Shows Effectiveness in Urinary Tract Infection
January 13, 2017
- SBI Biotech Licenses Autoimmune Disease Med to Kyowa Kirin
January 13, 2017
- Takeda Invests US$125 Million in Maverick for T-Cell Therapy, Buyout Eyed
January 13, 2017
- AbbVie’s 8-Week Hep C Med Delivers High SVR12 Rate in Japanese
January 13, 2017
- Imigran AG to Get Off Strong Start: Aspen Japan
January 12, 2017
- Astellas Bows Out from Flu Vaccine Development Pact with UMN
January 11, 2017
- Daiichi Sankyo to Shutter Indian Research Subsidiary
January 11, 2017
- Plavix AG Now Has All Same Indications as Originator
January 11, 2017
- Daiichi Sankyo Gets Japan Rights to Kite’s CAR T-Cell Therapy
January 11, 2017
- Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…